Hepatic, Intestinal, Renal, and Plasma Hydrolysis of Prodrugs in Human, Cynomolgus Monkey, Dog, and Rat: Implications for In Vitro–In Vivo Extrapolation of Clearance of Prodrugs

Hydrolysis plays an important role in metabolic activation of prodrugs. In the current study, species and in vitro system differences in hepatic and extrahepatic hydrolysis were investigated for 11 prodrugs. Ten prodrugs in the data set are predominantly hydrolyzed by carboxylesterases (CES), whereas olmesartan medoxomil is also metabolized by carboxymethylenebutenolidase (CMBL) and paraoxonase. Metabolic stabilities were assessed in cryopreserved hepatocytes, liver S9 (LS9), intestinal S9 (IS9), kidney S9 (KS9), and plasma from human, monkey, dog, and rat. Of all the preclinical species investigated, monkey intrinsic hydrolysis clearance obtained in hepatocytes (CLint,hepatocytes) were the most comparable to human hepatocyte data. Perindopril and candesartan cilexetil showed the lowest and highest CLint,hepatocytes, respectively, regardless of the species investigated. Scaled intrinsic hydrolysis clearance obtained in LS9 were generally higher than CLint,hepatocytes in all species investigated, with the exception of dog. In the case of human and dog intestinal S9, hydrolysis intrinsic clearance could not be obtained for CES1 substrates, but hydrolysis for CES2 and CMBL substrates was detected in IS9 and KS9 from all species. Pronounced species differences were observed in plasma; hydrolysis of CES substrates was only evident in rat. Predictability of human hepatic intrinsic clearance (CLint,h) was assessed for eight CES1 substrates using hepatocytes and LS9; extrahepatic hydrolysis was not considered due to high stability of these prodrugs in intestinal and kidney S9. On average, predicted oral CLint,h from hepatocyte data represented 20% of the observed value; the underprediction was pronounced for high-clearance prodrugs, consistent with the predictability of cytochrome P450/conjugation clearance from this system. Prediction bias was less apparent with LS9, in particular for high-clearance prodrugs, highlighting the application of this in vitro system for investigation of prodrugs.

[1]  I. Roots,et al.  Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. , 1998, British journal of clinical pharmacology.

[2]  A. Galetin,et al.  Characterization of In Vitro Glucuronidation Clearance of a Range of Drugs in Human Kidney Microsomes: Comparison with Liver and Intestinal Glucuronidation and Impact of Albumin , 2012, Drug Metabolism and Disposition.

[3]  A. Horita,et al.  Species Differences in Stereoselective Hydrolase Activity in Intestinal Mucosa , 1998, Pharmaceutical Research.

[4]  Malcolm Rowland,et al.  Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[5]  J. Devissaguet,et al.  Pharmacokinetics of perindopril and its metabolites in healthy volunteers , 1990, Fundamental & clinical pharmacology.

[6]  Sandip S Chavhan,et al.  Enhanced Antihypertensive Activity of Candesartan Cilexetil Nanosuspension: Formulation, Characterization and Pharmacodynamic Study , 2011, Scientia pharmaceutica.

[7]  A. Galetin,et al.  Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[8]  T. Saruta,et al.  Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS‐622) in humans , 1993, Biopharmaceutics & drug disposition.

[9]  E. Duysen,et al.  Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. , 2005, Biochemical pharmacology.

[10]  J Brian Houston,et al.  BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT , 2006, Drug Metabolism and Disposition.

[11]  Micheline Piquette-Miller,et al.  Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer , 2008, Drug Metabolism and Disposition.

[12]  Michael Gertz,et al.  Hepatocellular Binding of Drugs: Correction for Unbound Fraction in Hepatocyte Incubations Using Microsomal Binding or Drug Lipophilicity Data , 2008, Drug Metabolism and Disposition.

[13]  G. Geisslinger,et al.  Isolation and pharmacological characterization of microsomal human liver flumazenil carboxylesterase. , 1998, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[14]  Mary F Paine,et al.  THE HUMAN INTESTINAL CYTOCHROME P450 “PIE” , 2006, Drug Metabolism and Disposition.

[15]  B. Lenfant,et al.  Trandolapril: Pharmacokinetics of Single Oral Doses in Healthy Male Volunteers , 1994, Journal of cardiovascular pharmacology.

[16]  Fujun Li,et al.  Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. , 2008, Journal of pharmaceutical sciences.

[17]  P. Welling,et al.  The Clinical Pharmacokinetics of Quinapril , 1989, Angiology.

[18]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[19]  A. Galetin,et al.  Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance , 2009, Pharmaceutical Research.

[20]  E. T. Williams,et al.  Characterization of the Expression and Activity of Carboxylesterases 1 and 2 from the Beagle Dog, Cynomolgus Monkey, and Human , 2011, Drug Metabolism and Disposition.

[21]  Aleksandra Galetin,et al.  Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data , 2011, Drug Metabolism and Disposition.

[22]  I. Tamai,et al.  Effect of milk on the pharmacokinetics of oseltamivir in healthy volunteers. , 2011, Journal of pharmaceutical sciences.

[23]  V. Stella.  Prodrugs: Some thoughts and current issues. , 2010, Journal of pharmaceutical sciences.

[24]  G. Amidon,et al.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. , 2013, Molecular pharmaceutics.

[25]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[26]  M. Miura,et al.  Involvement of Carboxylesterase 1 and 2 in the Hydrolysis of Mycophenolate Mofetil , 2010, Drug Metabolism and Disposition.

[27]  S. Brechbühler,et al.  Pharmacokinetics of the angiotensin converting enzyme inhibitor benazepril.HCl (CGS 14 824 A) in healthy volunteers after single and repeated administration. , 1989, Biopharmaceutics & drug disposition.

[28]  S. Komuro,et al.  Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. , 2011, Drug metabolism and pharmacokinetics.

[29]  Hannu Raunio,et al.  Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.

[30]  Teruko Imai,et al.  Human carboxylesterase isozymes: catalytic properties and rational drug design. , 2006, Drug metabolism and pharmacokinetics.

[31]  Aleksandra Galetin,et al.  Methods for predicting in vivo pharmacokinetics using data from in vitro assays. , 2008, Current drug metabolism.

[32]  Bill J Smith,et al.  Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches , 2009, Journal of clinical pharmacology.

[33]  Mitsunori Kato,et al.  Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine , 2010, The Journal of Biological Chemistry.

[34]  Hans Lennernäs,et al.  Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. , 2014, Molecular pharmaceutics.

[35]  Teruko Imai,et al.  Carboxylesterase in the liver and small intestine of experimental animals and human. , 2007, Life sciences.

[36]  J. Mcewen,et al.  The pharmacokinetics and bioavailability of cilazapril in normal man. , 1989, British journal of clinical pharmacology.

[37]  D. Murry,et al.  Hydrolysis of Capecitabine to 5′-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide , 2005, Journal of Pharmacology and Experimental Therapeutics.

[38]  Zhiyang Zhao,et al.  Esterase activities in the blood, liver and intestine of several preclinical species and humans. , 2009, Drug metabolism letters.

[39]  Kayoko Ohura,et al.  Species difference of esterase expression and hydrolase activity in plasma. , 2012, Journal of pharmaceutical sciences.

[40]  Masakiyo Hosokawa,et al.  Structure and Catalytic Properties of Carboxylesterase Isozymes Involved in Metabolic Activation of Prodrugs , 2008, Molecules.

[41]  T. Fukami,et al.  The emerging role of human esterases. , 2012, Drug metabolism and pharmacokinetics.

[42]  M Hosokawa,et al.  The mammalian carboxylesterases: from molecules to functions. , 1998, Annual review of pharmacology and toxicology.

[43]  T. Izumi,et al.  Different Hydrolases Involved in Bioactivation of Prodrug-Type Angiotensin Receptor Blockers: Carboxymethylenebutenolidase and Carboxylesterase 1 , 2013, Drug Metabolism and Disposition.

[44]  F. Jané,et al.  Influence of renal function on the pharmacokinetics of ramipril (HOE 498). , 1987, The American journal of cardiology.

[45]  Kayoko Ohura,et al.  The role of intestinal carboxylesterase in the oral absorption of prodrugs. , 2010, Current drug metabolism.

[46]  P. Taylor,et al.  Current progress on esterases: from molecular structure to function. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[47]  E. T. Williams,et al.  Genomic analysis of the carboxylesterases: identification and classification of novel forms. , 2010, Molecular phylogenetics and evolution.

[48]  B. Rangoonwala,et al.  Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man. , 1995, Current medical research and opinion.

[49]  T. Izumi,et al.  Paraoxonase 1 as a Major Bioactivating Hydrolase for Olmesartan Medoxomil in Human Blood Circulation: Molecular Identification and Contribution to Plasma Metabolism , 2012, Drug Metabolism and Disposition.

[50]  Aleksandra Galetin,et al.  Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes , 2009, Drug Metabolism and Disposition.

[51]  V. Herring,et al.  The Role of Human Carboxylesterases in Drug Metabolism: Have We Overlooked Their Importance? , 2013, Pharmacotherapy.

[52]  Yuichiro Sato,et al.  Simultaneous Absolute Protein Quantification of Carboxylesterases 1 and 2 in Human Liver Tissue Fractions using Liquid Chromatography-Tandem Mass Spectrometry , 2012, Drug Metabolism and Disposition.

[53]  J. Hochman,et al.  Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[54]  A. Dahan,et al.  Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach , 2012, Expert opinion on drug delivery.